2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024 PMID: 39495965, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesityGLP-1 programs the neurovascular landscape
Chen B, Yu X, Horvath-Diano C, Ortuño M, Tschöp M, Jastreboff A, Schneeberger M. GLP-1 programs the neurovascular landscape. Cell Metabolism 2024, 36: 2173-2189. PMID: 39357509, DOI: 10.1016/j.cmet.2024.09.003.Peer-Reviewed Original ResearchConceptsGLP-1R agonismGLP-1RMetabolic healthChronic low-grade inflammationLow-grade inflammationGlucagon-like peptide-1 receptorPersistent health issuesCognitive well-beingNutrient-rich foodsPeptide-1 receptorMetabolic syndromeHealth issuesMetabolic defectsBrain healthMetabolic environmentObesityWell-beingWeight lossHealthMetabolic conditionsAgonismNeurological conditionsEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2
2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionChampioning the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF)
Weghuber D, Khandpur N, Boyland E, Mazur A, Frelut M, Forslund A, Vlachopapadopoulou E, Erhardt É, Vania A, Molnar D, Ring‐Dimitriou S, Caroli M, Mooney V, Forhan M, Ramos‐Salas X, Pulungan A, Holms J, O'Malley G, Baker J, Jastreboff A, Baur L, Thivel D. Championing the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF). Pediatric Obesity 2023, 18: e13024. PMID: 37002830, DOI: 10.1111/ijpo.13024.Peer-Reviewed Original ResearchNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgentsWhen Weight Impacts Health
Aronne L, Bramblette S, Ingelfinger J, Jastreboff A, Machineni S, Massie N, Rosen C. When Weight Impacts Health. New England Journal Of Medicine 2023, 388: e2. PMID: 36630621, DOI: 10.1056/nejmp2215794.Peer-Reviewed Original Research
2022
Weight and Health — Pathophysiology and Therapies
Aronne L, Bramblette S, Huett-Garcia A, Ingelfinger J, Jastreboff A, Machineni S, Massie N, Rosen C. Weight and Health — Pathophysiology and Therapies. New England Journal Of Medicine 2022, 387: e62. PMID: 36516089, DOI: 10.1056/nejmp2214423.Peer-Reviewed Original ResearchObstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planObstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. American Journal Of Kidney Diseases 2022, 80: 783-793. PMID: 36280397, DOI: 10.1053/j.ajkd.2022.06.007.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsManagement of obesityLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action plan
2021
Treating the Chronic Disease of Obesity
Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Medical Clinics Of North America 2021, 105: 983-1016. PMID: 34688422, DOI: 10.1016/j.mcna.2021.06.005.Peer-Reviewed Original ResearchConceptsChronic diseasesIntensive lifestyle interventionAvailable therapeutic modalitiesPrimary care providersTreatable chronic diseaseCare of patientsAntiobesity pharmacotherapiesBariatric surgeryLifestyle interventionSafe therapyComprehensive careTherapeutic modalitiesCare providersTreatment approachesObesityPatientsDiseaseCarePharmacotherapySurgeryTherapyDiagnosisCOVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society
Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity 2021, 29: 1575-1579. PMID: 34212511, PMCID: PMC8441899, DOI: 10.1002/oby.23251.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineObesity SocietyCOVID-19-associated hospitalizationPosition statementEfficacy of vaccinesSARS-CoV-2Pfizer-BioNTechAvailable vaccinesUS FoodDrug AdministrationObesityVaccineEmergency useHigh efficacyPeer-reviewed literatureScientific evidenceCOVID-19EfficacyTime of publicationBriefing documentsDefinitive wayHospitalizationPatientsVaccinationAdministrationLower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology 2021, 47: 543-552. PMID: 34294874, PMCID: PMC8674236, DOI: 10.1038/s41386-021-01111-5.Peer-Reviewed Original ResearchConceptsStress-related psychiatric disordersBody mass indexLower synaptic densitySynaptic densityPsychiatric disordersPsychiatric diagnosisOverweight/obesityNormal-weight individualsNormal-weight participantsSerious medical conditionPositron emission tomographyStress-related psychopathologyDorsolateral prefrontal cortexOverweight/Mass indexWeight participantsWeight individualsHealthy controlsTension/anxietyAssociated symptomatologyMedical conditionsIntervention development effortsObesityCognitive alterationsPsychiatric groupsDietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee
Kidambi S, Batsis JA, Donahoo WT, Jastreboff AM, Kahan S, Saunders KH, Heymsfield SB. Dietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee. Obesity 2021, 29: 1095-1098. PMID: 34159756, DOI: 10.1002/oby.23189.Peer-Reviewed Original Research
2019
Treatment of Adolescent Obesity in 2020
Cardel MI, Jastreboff AM, Kelly AS. Treatment of Adolescent Obesity in 2020. JAMA 2019, 322: 1707-1708. PMID: 31566652, PMCID: PMC7268517, DOI: 10.1001/jama.2019.14725.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
Obesity as a Disease: The Obesity Society 2018 Position Statement
Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity 2018, 27: 7-9. PMID: 30569641, DOI: 10.1002/oby.22378.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPreventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study
Jastreboff AM, Chaplin TM, Finnie S, Savoye M, Stults-Kolehmainen M, Silverman WK, Sinha R. Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study. The Journal Of Pediatrics 2018, 202: 136-142.e1. PMID: 30241766, PMCID: PMC6203652, DOI: 10.1016/j.jpeds.2018.07.011.Peer-Reviewed Original ResearchConceptsChildhood obesityChild body mass indexGroup interventionPhysical activity counselingRandomized pilot studyBody mass indexChildhood obesity riskControl group interventionEarly childhood obesityStress interventionsActivity counselingMass indexObesity riskPhysical activityTherapeutic mechanismObesityGroup attendanceRisk 2Pilot studyInterventionSignificant increaseLow-income parentsGreater improvementRiskParent-child dyads
2015
Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance
Van Name M, Giannini C, Santoro N, Jastreboff AM, Kubat J, Li F, Kursawe R, Savoye M, Duran E, Dziura J, Sinha R, Sherwin RS, Cline G, Caprio S. Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance. Obesity 2015, 23: 653-661. PMID: 25645909, PMCID: PMC4548801, DOI: 10.1002/oby.21019.Peer-Reviewed Original ResearchConceptsAcyl ghrelinObese insulinGlucose ingestionInsulin resistanceObese adolescentsCross-over designFructose ingestionGut hormonesChildhood obesityInsulin sensitivityFructose consumptionEffect of glucoseDiminished suppressionRandom orderIngestionObesityPYYAdolescentsInsulinSuppression differencesGlucoseMinutesResponseGhrelinOIR
2013
Linking an Obesity-Associated Gene Variant, Ghrelin, and the Brain
Jastreboff A. Linking an Obesity-Associated Gene Variant, Ghrelin, and the Brain. Science Translational Medicine 2013, 5 DOI: 10.1126/scitranslmed.3007044.Peer-Reviewed Original Research